ArticleKidney international reports2026
Stenosis in Mature Arteriovenous Fistulas Characterized by Contractile Smooth Muscle Cells and Versican.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Introduction: Stenosis occurs in 20% to 40% of mature arteriovenous fistulas (AVFs). Alterations of the vessel wall composition in stenosis should provide insights into its pathogenesis. However, there is a dearth of studies examining the vessel wall composition of AVF with secondary failure. Methods: Twenty-one AVF explants were used. Cellular (vascular smooth muscle cells [vSMCs]) and noncellular components (collagen and extracellular matrix [ECM]) were quantified using a customized machine-learning approach. Results: AVFs were explanted for aneurysms (16/21), pseudoaneurysms (2/21), or cosmetic reasons (3/21). Fifteen of the AVFs had a stenotic lesion. Proteoglycans and collagen predominated over vSMCs in the AVF wall and showed disruptions along the needle tracks. The stenotic wall showed compact collagen organization and higher expression of perlecan, versican, and versikine, and a linear correlation between versican and versikine. vSMCs in stenosis showed higher myosin heavy chain 11 (MYH11), Calponin, and smooth muscle actin (contractile and/or quiescent markers) than Ki67, a proliferative marker, without an increase in osteopontin (a secretory marker). Proliferating cells were located > 50 to 100 microns from the subendothelium. Conclusion: Advanced stenosis in mature AVFs are characterized by contractile vSMC phenotype and predominated by extracellular and proteoglycan-rich remodeling raising a possibility of AVF stenotic lesions as a temporal continuum in which vSMCs initially adopt a synthetic and/or proliferative phenotype during stenosis formation and subsequently contractile phenotype as the stenosis stabilizes. Although providing potential insights into the heterogeneous response of paclitaxel-coated devices in AVF stenosis, this study underscores the need for a deeper understanding of the biology of stenosis in mature AVFs and the use of targeted therapies for specific components in AVF stenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.